We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.59%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$17.8M
Cap. Flow
% of AUM
-10.58%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$947K |
| 2 |
Moderna
MRNA
|
+$899K |
| 3 |
Meta Platforms (Facebook)
META
|
+$895K |
| 4 |
Netflix
NFLX
|
+$876K |
| 5 |
Chipotle Mexican Grill
CMG
|
+$852K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$1.01M |
| 2 |
Progressive
PGR
|
+$999K |
| 3 |
Stryker
SYK
|
+$984K |
| 4 |
Republic Services
RSG
|
+$973K |
| 5 |
Linde
LIN
|
+$966K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Zentalis Pharmaceuticals
ZNTL
$321M
| $125K | 0.07% |
4,415
-650
| -13% | -$15.6K |
|
|
AMAM
327
DELISTED
Ambrx Biopharma Inc
AMAM
| $123K | 0.07% |
+7,468
| New | +$93.9K |
|
328
Phathom Pharmaceuticals
PHAT
$953M
| $122K | 0.07% |
+8,515
| New | +$98.2K |
|
|
VERV
329
DELISTED
Verve Therapeutics
VERV
| $119K | 0.07% |
6,359
+1,888
| +42% | +$31.4K |
|
330
AnaptysBio
ANAB
$1.59B
| $119K | 0.07% |
5,859
+2,411
| +70% | +$48.9K |
|
331
Mineralys Therapeutics
MLYS
$2.4B
| $116K | 0.07% |
+6,817
| New | +$102K |
|
332
Revolution Medicines
RVMD
$40B
| $115K | 0.07% |
4,306
+137
| +3% | +$3.36K |
|
|
CMPS
333
Compass Pathways
CMPS
$1.52B
| $114K | 0.07% |
13,799
+3,756
| +37% | +$31.9K |
|
334
Relay Therapeutics
RLAY
$4.06B
| $114K | 0.07% |
9,092
+3,306
| +57% | +$41.1K |
|
335
PMV Pharmaceuticals
PMVP
$62.9M
| $114K | 0.07% |
18,184
+7,762
| +74% | +$40.7K |
|
336
Keros Therapeutics
KROS
$202M
| $113K | 0.07% |
2,818
+801
| +40% | +$35.1K |
|
337
Geron
GERN
$949M
| $113K | 0.07% |
35,190
-7,861
| -18% | -$22.4K |
|
338
Arcturus Therapeutics
ARCT
$164M
| $113K | 0.07% |
3,936
-1,431
| -27% | -$39K |
|
339
Zymeworks
ZYME
$1.69B
| $113K | 0.07% |
13,054
-2,705
| -17% | -$24.2K |
|
340
Arcus Biosciences
RCUS
$3.5B
| $113K | 0.07% |
5,548
+2,538
| +84% | +$48.3K |
|
|
EQRX
341
DELISTED
EQRx, Inc. Common Stock
EQRX
| $112K | 0.07% |
60,076
+18,613
| +45% | +$33.3K |
|
|
CVAC
342
DELISTED
CureVac
CVAC
| $111K | 0.07% |
10,692
-3,422
| -24% | -$30.6K |
|
|
DVAX
343
DELISTED
Dynavax Technologies
DVAX
| $111K | 0.07% |
8,616
-140
| -2% | -$1.59K |
|
344
Erasca
ERAS
$6.55B
| $111K | 0.07% |
40,125
+19,223
| +92% | +$54.8K |
|
345
Regenxbio
RGNX
$622M
| $110K | 0.07% |
5,523
+1,266
| +30% | +$24.4K |
|
346
Arrowhead Research
ARWR
$12B
| $110K | 0.07% |
3,077
-1
| -0% | -$34 |
|
347
Liquidia Corp
LQDA
$7.51B
| $108K | 0.06% |
+13,817
| New | +$107K |
|
348
Allogene Therapeutics
ALLO
$604M
| $108K | 0.06% |
21,813
+8,742
| +67% | +$47.3K |
|
|
MRUS
349
DELISTED
Merus
MRUS
| $108K | 0.06% |
4,103
-3,202
| -44% | -$70.1K |
|
350
Replimune Group
REPL
$724M
| $108K | 0.06% |
4,631
+1,008
| +28% | +$19.7K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, Virtus ETF Advisers held 495 positions worth $169M, down 7.2% from $182M the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Virtus ETF Advisers withdrew a net $17.8M in Q2 2023, closing 60 positions and reducing 257 holdings. Its most notable exit was Activision Blizzard, an estimated $1.01M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in NVIDIA worth $1.21M.
- Virtus ETF Advisers's largest Q2 2023 buy was NVIDIA: 28,520 shares worth $1.21M.
- Virtus ETF Advisers added most to Moderna in Q2 2023, an estimated $899K increase.
- Virtus ETF Advisers's biggest Q2 2023 reduction was Dow Inc, cutting an estimated $898K.
- Virtus ETF Advisers fully exited Activision Blizzard in Q2 2023, selling an estimated $1.01M.
- Virtus ETF Advisers's ten largest holdings make up 6.3% of its $169M portfolio in Q2 2023.
- Virtus ETF Advisers opened 55 new positions and closed 60 in Q2 2023.
- Virtus ETF Advisers's portfolio value fell 7.2% quarter-over-quarter to $169M.
Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.